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Objectives We assessed the incremental value of baseline Q waves over time from symptom onset as a marker of clinical
outcome in ST-segment elevation myocardial infarction (STEMI).
Background Time from symptom onset is a central focus in STEMI patients. The presence of Q waves on the baseline electro-
cardiogram (ECG) has been suggested to be of incremental value to time from symptom onset in evaluating clin-
ical outcomes.
Methods We evaluated baseline Q waves and ST-segment resolution 30 min after primary percutaneous intervention (PCI)
ECGs in 4,530 STEMI patients without prior infarction. Additionally, peak biomarkers; 90-day mortality; and the
composite of death, congestive heart failure (CHF), or cardiogenic shock were assessed.
Results Fifty-six percent of patients had baseline Q waves: they were older, more frequently male and diabetic, and had a
more advanced Killip class. Patients with baseline Q waves had greater mortality and a higher composite rate of
death, CHF, and shock versus patients without baseline Q waves at 90 days (5.3% vs. 2.1% and 12.1% vs. 4.8%, re-
spectively, both p  0.001). Complete ST-segment resolution was highest, whereas 90-day mortality and the compos-
ite outcome were lowest among those randomized 3 h without baseline Q waves. After multivariable adjustment,
baseline Q-wave but not time from symptom onset was significantly associated with a 78% relative increase in the
hazard of 90-day mortality and a 90% relative increase in the hazard of death, shock, and CHF.
Conclusions Baseline Q waves in STEMI patients treated with primary PCI provide an independent prognostic marker of clini-
cal outcome. These data might be useful in designing future clinical trials as well as in evaluating patients for
triage and potential transfer for planned primary PCI. (Pexelizumab in Conjunction With Angioplasty in Acute
Myocardial Infarction [APEX-AMI]; NCT00091637) (J Am Coll Cardiol 2009;53:1503–9) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.046D
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Cime from symptom onset has become a central focus in the
iagnosis, triage, and management of patients with ST-
egment elevation myocardial infarction (STEMI) (1,2).
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Prognostic Value of Baseline Q Waves in STEMI April 28, 2009:1503–9with experimental models that
underscore the clinical ambiguity
in identifying the stage of evolu-
tion of STEMI in humans (3).
Accordingly, several efforts have
been made to evaluate elements
of the electrocardiogram (ECG)
at the time of presentation of
STEMI in hopes of providing
additional insight into the stage
of evolution of the process. Be-
cause the presence of baseline Q
waves has been demonstrated to
rovide incremental value over the interval between symp-
om onset and presentation in predicting 30-day mortality
n STEMI patients receiving streptokinase, it constitutes a
otential marker of the stage of infarct development (4,5).
e recently provided support for this concept in the
SSENT (Assessment of the Safety and Efficacy of a New
reatment Strategy for Acute Myocardial Infarction) IV-
ercutaneous coronary intervention (PCI) study, because
atients within the facilitated fibrinolytic group presenting
ore than 3 h after symptom onset with baseline Q waves
ad worse outcomes (6). Whether a similar relationship
xists in the expanding cohort of STEMI patients treated
ith primary PCI is unknown but important to ascertain,
iven that the association between time from symptom
nset to reperfusion with PCI seems less strongly related to
utcome than with fibrinolysis (7,8). Accordingly, we eval-
ated whether the aforementioned relationship between
-wave presence and clinical outcomes exists in a large
ontemporary cohort of PCI-treated STEMI patients en-
olled in the APEX-AMI (Assessment of Pexelizumab in
cute Myocardial Infarction) trial.
ethods
he APEX-AMI trial was a multicenter, randomized,
ouble-blind, placebo-controlled trial of intravenous pexeli-
umab administered immediately before primary PCI for
lectrocardiographically high-risk STEMI patients (9). The
rimary end point of the present study was 90-day mortality
nd the composite of death, centrally adjudicated congestive
eart failure (CHF), or cardiogenic shock at 90 days.
ecause no significant difference was observed in the pri-
ary end point between the treatment and placebo arms,
oth arms were pooled for the current analysis.
A total of 5,745 patients were enrolled in the trial
ccording to the following specific entry criteria described
reviously (10): briefly, patients were18 years of age, with
ymptom onset 6 h, and had an ECG indicative of acute
TEMI that fulfilled any of the following 3 criteria:
2-mm ST-segment elevation in 2 anterior or lateral leads;
2-mm ST-segment elevation in 2 inferior leads coupled
ith ST-segment depression in 2 contiguous anterior leads
Abbreviations
and Acronyms
CHF  congestive heart
failure
ECG  electrocardiogram
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionor a total ST-segment deviation of 8 mm; or new left tundle branch block with at least 1-mm concordant ST-
egment elevation.
CG analysis. All baseline and 30-min post-PCI ECGs
ere evaluated centrally at the ECG core laboratories
Canadian VIGOUR Centre, Edmonton, Canada and
uke Clinical Research Institute, Durham, North Caro-
ina) without knowledge of treatment assignment and
utcomes.
The Q-wave or Q-wave equivalent was determined at
aseline ECG with the Selvester QRS screening criteria
11): a Q-wave of 30 ms in aVF (inferior); 40 ms in I
nd aVL (lateral), or 40 ms in 2 of V4, V5, or V6
apical); or any Q-wave in V2 (anterior). As well, Q-wave
quivalents were defined as an R-wave of 40 ms in V1
posterior) or an R-wave 0.1 mV and 10 ms in V2
anterior).
To assess the degree of ST-segment resolution after PCI,
e used Schröder’s method (12), in which the degree of
T-segment resolution at 30 min after PCI was calculated
elative to the baseline ST-segment elevation (or deviation if
resent): complete resolution at 70%, partial resolution at
0% to 70%, and no resolution at 30%. The degree of
T-segment deviation was determined at the J-point with
agnified calipers. For anterior infarction, the total ST-
egment deviation was the sum of ST-segment elevation in
eads I, aVL, and V1 to V6 added to the sum of ST-segment
epression in leads II, III, and aVF. For inferior infarction,
otal ST-segment deviation was the sum of ST-segment
levation in leads II, III, aVF, V5, and V6 added to the sum
f ST-segment depression in leads V1 to V4. There was
xcellent interobserver agreement (96%) on the basis of both
ssessments of ST-segment deviation and Q waves.
Additionally, biomarkers of myocardial necrosis (i.e.,
eak samples of creatine kinase [U/l], creatine kinase
yocardial band [g/l], troponin-I [g/l], or troponin-T
g/l]) were obtained. Peak samples of these biomarkers
ere collected and processed according to local protocols.
amples for at least 1 biomarker for myocardial necrosis
ere available for all in the current study population.
tatistical analysis. Descriptive statistics were reported as
ercentages for categorical variables with comparisons be-
ween patient groups made with the chi-square test, medi-
ns with 25th and 75th percentiles, and the nonparametric
ann-Whitney U test for continuous variables. Time from
ymptom onset to PCI was considered as a dichotomous
ariable with 3 h as the cut point (to correspond to current
merican College of Cardiology/American Heart Associa-
ion guidelines;3 h vs.3 h). The analysis of time to PCI
reated as a continuous variable is also presented in the
ccompanying online appendix.
Associations between baseline Q-wave and the time to
he (first) event (i.e., death or death/CHF/shock) were
xamined with Kaplan-Meier survival estimates (i.e., unad-
usted survival analyses) with pairwise comparisons based on
he log-rank test. Further stratification of Q-wave according
o myocardial infarction (MI) location was also examined.
Selected Baseline Characteristics According to Q-Wave and Time From Symptom Onset to PCI
Table 1 Selected Baseline Characteristics According to Q-Wave and Time From Symptom Onset to PCI
All Patients Time From Symptom Onset to PCI <3 h Time From Symptom Onset to PCI >3 h
No Q-Wave Q-Wave p Value No Q-Wave Q-Wave p Value No Q-Wave Q-Wave p Value
n 2,016 2,514 890 940 1,126 1,574
Age, yrs 60 (51, 70) 61 (53, 71) 0.001 58 (50, 68) 60 (52, 69) 0.005 62 (53, 71) 62 (53, 72) 0.036
Female, % 26.4 21.0 0.001 21.5 17.4 0.030 30.4 23.2 0.001
Diabetes mellitus, % 12.4 15.7 0.001 9.9 13.9 0.008 14.3 16.8 0.082
Hypertension, % 45.8 46.9 0.455 40.3 41.7 0.553 50.1 50.0 0.964
Heart rate, beats/min 72 (62, 84) 76 (66, 88) 0.001 72 (61, 83) 75 (65, 85) 0.001 72 (62, 84) 78 (67, 89) 0.001
Systolic blood pressure, mm Hg 131 (116, 150) 135 (119, 150) 0.077 130 (115, 148) 130 (116, 148) 0.746 134 (117, 152) 136 (120, 151) 0.129
Killip 1, % 7.9 11.0 0.001 6.5 10.2 0.004 9.1 11.4 0.047
Inferior MI, % 57.1 29.3 0.001 56.7 27.8 0.001 57.4 30.1 0.001
Creatinine clearance, ml/min 85.3 (66.1, 108.7) 82.7 (64.4, 107.9) 0.096 89.8 (69.5, 111.3) 86.5 (68.7, 108.3) 0.120 81.8 (64.2, 105.7) 80.8 (61.9, 107.5) 0.508
Baseline ST-segment deviation, mm 13 (9, 18) 14.5 (10.0, 20.5) 0.001 13 (9.5, 18.5) 15 (10.0, 21.5) 0.001 13 (9, 17.5) 14 (9.5, 20) 0.001
Symptom onset to baseline ECG, h 1.65 (1, 2.64) 1.95 (1.18, 3.12) 0.001 1.03 (0.68, 1.43) 1.08 (0.73, 1.52) 0.019 2.47 (1.80, 3.41) 2.78 (1.97, 3.73) 0.001
Symptom onset to PCI, h 3.13 (2.37, 4.13) 3.30 (2.53, 4.33) 0.001 2.32 (1.95, 2.67) 2.42 (2.00, 2.72) 0.014 4.07 (3.48, 4.78) 4.12 (3.48, 4.95) 0.103
Median (25th, 75th percentile) presented for continuous variables.
ECG  electrocardiogram; MI  myocardial infarction; PCI  percutaneous coronary intervention.
Selected Pre- and Post-PCI Indicators and Peak Biomarkers According to Q-Wave and Time From Symptom Onset to PCI
Table 2 Selected Pre- and Post-PCI Indicators and Peak Biomarkers According to Q-Wave and Time From Symptom Onset to PCI
All Patients Time From Symptom Onset to PCI <3 h Time From Symptom Onset to PCI >3 h
No Q-Wave Q-Wave p Value No Q-Wave Q-Wave p Value No Q-Wave Q-Wave p Value
n 2,016 2,514 890 940 1,126 1,574
Pre-PCI TIMI flow grade, % 0.001 0.176 0.001
0/1 72.2 77.6 74.6 77.3 70.3 77.7
2 15.3 13.4 13.6 12.9 16.7 13.7
3 12.5 9.1 11.8 9.8 13.1 8.6
Post-PCI TIMI flow grade, % 0.001 0.010 0.021
0/1 2.3 2.1 2.3 2.0 2.2 2.2
2 4.9 8.1 3.7 6.4 5.9 9.1
3 92.8 89.8 93.9 91.7 91.9 88.7
ST-segment deviation resolution, % 0.001 0.001 0.001
30 11.1 17.3 11.1 16.1 11.2 17.9
30–70 27.2 39.7 24.9 38.1 29.0 40.6
70 61.7 43.1 64.0 45.7 59.8 41.5
Peak CK, U/l 1,504 (708, 2,901) 2,270 (1,108, 3,865) 0.001 1,435 (677, 2,788) 2,133 (1,018, 3,771) 0.001 1,570 (746, 2,990) 2,366 (1,159, 3,942) 0.001
Peak CKMB, g/l 137 (59.7, 269) 172 (75, 301) 0.001 133 (54, 266) 174 (77, 311) 0.001 139 (63, 272) 171 (73, 300) 0.001
Peak TnT, g/l [n] 3.9 (1.6, 7.0) [544] 5.6 (2.7, 10.9) [649] 0.001 3.1 (1.4, 6.5) [281] 4.9 (2.2, 9.8) [277] 0.001 4.6 (2.0, 7.3) [263] 6.1 (2.9, 11.7) [372] 0.001
Peak TnI, g/l [n] 46.9 (16.5, 95.6) [1,055] 77.0 (32.3, 132.3) [1,354] 0.001 41.4 (15.8, 95.8) [426] 81.5 (28.4, 145.1) [469] 0.001 49.7 (17.6, 95.6) [629] 75.6 (35.0, 128.2) [885] 0.001
Median (25th, 75th percentile) presented for continuous variables.
CK  creatine kinase; CKMB  creatine kinase myocardial band; TIMI  Thrombolysis In Myocardial Infarction; TnI  troponin-I; TnT  troponin-T; other abbreviations as in Table 1.
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Prognostic Value of Baseline Q Waves in STEMI April 28, 2009:1503–9he relationship between time from symptom onset to PCI
i.e., first balloon inflation) and these outcomes was also
xamined. These associations were then adjusted for patient
haracteristics via Cox proportional-hazards regression. Un-
djusted and adjusted hazard ratios and corresponding 95%
onfidence intervals are reported. Interactions between
aseline Q-wave and MI location (inferior vs. noninferior
nfarction) and baseline Q-wave and time from symptom
nset to PCI were also tested. The relative contributions of
aseline Q-wave and time to PCI were calculated as the
ercent of chi-square for each outcome model. The
receding analyses were conducted in patients with Q waves
n the distribution of their qualifying ST-segment elevation,
nd patients with prior MI were excluded to remove any
otential confounding of Q-wave ascertainment during the
cute index event. All tests were 2-sided with a 5% level of
ignificance. All analyses were performed with the use of
AS statistical software (version 9.1.3, SAS Institute, Cary,
orth Carolina).
Figure 1 Kaplan-Meier Curve by Baseline Q-Wave
Kaplan-Meier curve for 90-day (A) mortality by baseline Q-wave and (B) death/conesults
f the 5,745 patients enrolled in the APEX-AMI trial,
,530 patients were considered in the current analysis; 559
atients were excluded, because they had missing (n  12)
r noninterpretable ECGs (n  206) or did not undergo
rimary PCI (n  341). Six hundred fifty-six patients were
lso excluded because of a prior history of MI and/or Q
aves outside of the acute MI territory.
In Table 1, selected clinical baseline characteristics are
rovided along with key time points in the interval between
ymptom onset and treatment. Among all patients (left
anel), approximately 56% had a Q-wave on their baseline
CG. Such patients were slightly older, more frequently
ale and diabetic, and had a more advanced Killip class.
hey were less likely to have inferior MIs and had a greater
xtent of cumulative ST-segment deviation on the baseline
CG. Symptom onset duration to baseline ECG and to
CI was approximately 18 and 10 min longer, respectively,
heart failure (CHF)/shock by baseline Q-wave.gestive
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April 28, 2009:1503–9 Prognostic Value of Baseline Q Waves in STEMIn patients with Q waves. When patients were further
tratified by the conventional 3-h time frame from symptom
nset to PCI (Table 1, middle and right panel), the
forementioned distinguishing features seen for all pa-
ients were also evident.
In Table 2, with a similar format, culprit coronary artery
ow before and after PCI, ST-segment resolution 30 min
fter PCI, and peak biomarkers are shown. Patients pre-
enting with Q waves more often had impaired culprit
oronary vessel flow before PCI, less frequently achieved
omplete reperfusion as indicated by lesser Thrombolysis In
yocardial Infarction flow grade 3 after PCI, and less
ST-segment resolution in the 30-min after PCI ECG.
atients with Q waves at baseline also exhibited higher peak
iomarkers than those without baseline Q waves. When
atients were subdivided according to the 3-h time window
rom symptom onset, these distinguishing features between
Figure 2 Kaplan-Meier Curves by Baseline Q-Wave and MI Loca
Kaplan-Meier curves for 90-day (A) mortality by baseline Q-wave and myocardial in
(MI) location and (B) death/congestive heart failure (CHF)/shock by baseline Q-wa-wave and non–Q-wave at baseline were consistent with
he overall group findings.
In Figure 1, cumulative 90-day outcomes (i.e., mortality
Fig. 1A] and composite of death, CHF, and cardiogenic
hock [Fig. 1B]) according to baseline Q-wave are shown. A
lear separation is evident, with patients without a Q-wave
n the baseline ECG experiencing fewer 90-day outcomes
han those with Q waves (mortality, 2.1% vs. 5.3%, p 
.001; death/CHF/shock, 4.8% vs. 12.1%, p  0.001).
imilarly, patients who underwent PCI within 3 h had
etter 90-day outcomes than those undergoing PCI later, as
vident by their mortality (3.1% vs. 4.5%, p  0.018) and
he composite measure of death/CHF/shock (6.7% vs.
0.3%, p  0.001), respectively. When the relationship
etween baseline Q-wave and outcomes was examined
ccording to MI location, patients with noninferior MI and
Q-wave at baseline consistently had the highest event rates
n
MI location.tion
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Prognostic Value of Baseline Q Waves in STEMI April 28, 2009:1503–9Fig. 2). Within noninferior MIs, a clear differentiation in
ortality existed between Q-wave and no Q-wave (Fig. 2A)
5.8% vs. 2.3%, p  0.001), whereas this relationship was
omewhat attenuated in inferior MIs (4.2% vs. 1.9%, p 
.004). Similar patterns were observed for the composite
utcome (Fig. 2B) (noninferior MI: 14.1% vs. 5.4%, p 
.001; inferior MI: 7.2% vs. 4.4%, p  0.008).
After multivariable adjustment, baseline Q-wave but not
ime from symptom onset to PCI was significantly associ-
ted with a 78% (relative) increase in the hazard of 90-day
ortality (Fig. 3). Baseline Q-wave was also related to a
0% (relative) increase in hazard of 90-day death/CHF/
hock (Fig. 3). Time to PCI was significantly associated
ith the composite outcome (Fig. 3), unlike the relationship
ith mortality. Of note, baseline Q-wave had a greater
ontribution to the prediction of the composite than time
rom symptom onset to PCI (8.8% vs. 3.2%, respectively).
nteractions of Q-wave with MI location or time to PCI
ere not statistically significant. Even when time to PCI
as examined in a continuous fashion, baseline Q-wave was
ignificantly associated with an increased hazard of both
eath and the composite end point and continued to provide
greater prognostic contribution relative to time to PCI.
urther details on this analysis are contained in the Online
ppendix.
iscussion
ur data, acquired in over 4,500 STEMI patients treated
ith primary PCI, provide novel and compelling evidence
bout the importance of a Q-wave on the baseline ECG as
n independent prognostic marker of clinical outcome.
Figure 3 Associations Between Baseline Q-wave and Time From
A  adjusted (death: age, systolic blood pressure, heart rate, Killip Class, myocar
gestive heart failure (CHF)/shock: age, sex, hypertension, systolic blood pressure,
segment deviation); CI  confidence interval; HR  hazard ratio; Sx  symptom oatients presenting within 6 h of symptom onset who
xhibit Q waves on their baseline ECG seem to have a
istinct clinical profile that portends more advanced disease
i.e., older men with diabetes, a more advanced Killip class,
ore frequent noninferior MI, greater baseline ST-segment
eviation, and delayed presentation). The strong relation-
hip between lesser ST-segment resolution after PCI (pre-
iously demonstrated as a key prognostic factor in this
opulation) (13) and Q-wave presence indicates less suc-
essful myocardial reperfusion with PCI and is further
upported by the greater peak biomarkers for myocardial
ecrosis. Hence, such patients would be expected to have
ess salvageable myocardium and worse clinical outcomes, as
e demonstrated. The reasons for the greater likelihood of
T-segment resolution among patients without baseline Q
aves are unclear but could relate to their shorter overall
schemic times, lesser tissue jeopardy as indicated by the
xtent of ST-segment deviation, and better pre-PCI culprit
oronary flow.
Our observations concur with ones we have previously
emonstrated on patients with baseline Q waves presenting
ore than 3 h from symptom onset undergoing facilitated
CI with fibrinolytic therapy in ASSENT 4-PCI (6). Such
atients had significantly higher mortality than those with-
ut baseline Q waves. The finding of greater ST-segment
esolution in patients without early Q-wave development
s also consistent with earlier work from our laboratory
nd that of others (5,14). Whereas it has been argued that
aseline Q waves are “a poor predictor of symptom
uration,” our data support prior observations from
brinolytic treated patients contending that they are
ptom Onset to PCI and 90-Day Clinical Outcomes
farction location, serum creatinine, baseline ST-segment deviation; death/con-
rate, Killip Class, myocardial infarction location, serum creatinine, baseline ST-
 unadjusted.Sym
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April 28, 2009:1503–9 Prognostic Value of Baseline Q Waves in STEMIndependent from time from symptom onset and likely
epresent a more accurate reflection of the wave front of
yocardial necrosis (15).
tudy limitations. The trial and ECG entry criteria, al-
hough broad, are not necessarily generalizable to all pa-
ients with STEMI. Our study population received timely
echanical reperfusion and high adherence to evidence-
ased medical therapy as previously reported (9). Whereas it
ould be argued that the 3-h time point we chose to classify
ime from symptom onset is arbitrary, we did so because it
s a conventional one used in contemporary guidelines (1) of
TEMI therapy to influence therapeutic choices: our results
ere not materially altered when time from symptom onset
o PCI was examined as a continuous variable (Online
ppendix). Importantly, although there was a tendency for
shorter time from symptom onset to be associated with
educed 90-day mortality, time did prove to be a statistically
ignificant independent covariate predicting the 90-day
omposite outcome. Minimizing the time from symptom
nset to reperfusion should remain a major treatment goal
egardless of the presence or absence of Q waves on the
aseline ECG.
onclusions
e have shown that the baseline ECG in STEMI provides
ritically important insight into the outcomes after mechan-
cal reperfusion that is independent of time from symptom
nset. Because baseline Q waves seem to provide a window
nto the stage of evolution of infarction, it might be useful
o incorporate them into the design and evaluation of future
linical trials aimed at salvaging ischemic myocardium: in
articular, specific reporting of baseline Q waves and en-
iching cohort samples according to this metric might be
orthwhile. Moreover, the use of baseline Q waves might
rove to be of assistance to frontline clinicians evaluating
TEMI patients (similar to those enrolled in the APEX-
MI trial) for triage and potential transfer to a tertiary
enter for planned PCI as well as the substantial proportion
f patients in whom the history of symptom onset is unclear
r unavailable. This deserves to be explored prospectively.
urtailing the interval between the onset of STEMI and
he symptoms that herald its occurrence and the achieve-
ent of prompt reperfusion remains a high priority.
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